Karessa Pharma Holding AB (publ)

Equities

KARE

SE0005506193

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm Other stock markets			5-day change	1st Jan Change
- ^SEK	-.--%		-14.69%	-26.06%

2020	Klaria Pharma Holding AB (publ.) (OM:KLAR) completed the acquisition of Karessa Pharma Holding AB (OM:KARE).	CI
2019	Klaria Pharma Holding AB (publ.) (OM:KLAR) agreed to acquire Karessa Pharma Holding AB (OM:KARE) for SEK 46.6 million.	CI

Karessa Pharma Holding AB Announces Board Appointments

October 22, 2019 at 05:00 am EDT

Karessa Pharma Holding AB (publ) announced the election of Kristina Lidén Mascher and Neal Meacham as new members of the board of directors for the period until the end of the annual general meeting 2020.

Latest news about Karessa Pharma Holding AB (publ)

Klaria Pharma Holding AB (publ.) (OM:KLAR) completed the acquisition of Karessa Pharma Holding AB (OM:KARE).	20-03-05	CI
Klaria Pharma Holding AB (publ.) (OM:KLAR) agreed to acquire Karessa Pharma Holding AB (OM:KARE) for SEK 46.6 million.	19-11-04	CI
Karessa Pharma Holding AB Announces Board Appointments	19-10-22	CI
Stefan Arver Appoints as New Member of Board of Directors of Karessa Pharma	15-02-06	CI

Chart Karessa Pharma Holding AB (publ)

Duration

Period

More charts

Company Profile

Karessa Pharma Holding AB (publ) is a Sweden-based pharmaceutical company with the goal of developing products based on a patented drug delivery platform with direct absorption of active substances from the oral cavity to the bloodstream. The drug delivery platform is in the form of buccal film, an alignate-based polymer film, which is applied to the oral mucosa and through it the drug is then rapidly delivered into the bloodstream, while the film dissolves without leaving any residues in the mouth. The Company's research and development projects are based on active substances that have already been approved for use as medicinal products in other forms, and include, among others, Karessa k03 vardenafil via buccal film for the treatment of erectile dysfunction and Karessa k21 midazolam via buccal film for the treatment of anxiety and epilepsy symptoms.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Drug Delivery Systems

	1st Jan change	Capi.
KARESSA PHARMA HOLDING AB (PUBL)	-26.06%	2.85M
SEDANA MEDICAL AB	-11.92%	187M

Drug Delivery Systems